Technology stocks remained higher Thursday’s afternoon trade with shares of technology companies in the S&P 500 advancing more than 0.7%.
On Thursday, among technology stocks shares of Nokia Corporation (NYSE:NOK), gained 2.11% to $7.27, after it received a price target enhance from RBC Capital Markets.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally. The company operates through four segments: Mobile Broadband, Global Services, HERE, and Nokia Technologies.
Shares of Groupon, Inc. (NASDAQ:GRPN), inclined 2.21% to $5.54, during its last trading session.
On June 5, Blue Calypso, Inc. (BCYP), developer of patented mobile consumer shopping engagement solutions for retailers and product manufacturers, declared the Court has reset a Claim Construction Hearing, or “Markman hearing” for July 8, 2015 in the Eastern District of Texas for Blue Calypso’s patent infringement lawsuits against Groupon (GRPN), Foursquare, Yelp (YELP) and IZEA. The hearing had been planned for Jun 29, 2015. Judge Rodney Gilstrap will preside.
Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount worldwide. It also offers deals on products for which it acts as the merchant of record.
Finally, Johnson & Johnson (NYSE:JNJ), ended its last trade with 1.65% gain, and closed at $100.36.
Johnson & Johnson, named Dr. Bert Vogelstein of Johns Hopkins University, Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute, the winner of the 2015 Dr. Paul Janssen Award for Biomedical Research for his breakthroughs in oncology research, which have spanned more than two decades and have formed the basis of modern cancer research.
Dr. Vogelstein was honored last night during a reception at the 2015 BIO International Convention in Philadelphia.
“Dr. Vogelstein’s work forms the paradigm for understanding how nearly all forms of human tumors arise and progress,” said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “His discoveries triggered a new wave of innovation in the field, resulting in transformational solutions for patients. It is a great honor to recognize the work of researchers like Dr. Vogelstein, who embody the same tenacity and commitment to improving human health as Dr. Paul.”
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
